SCHEMBL448212

SCHEMBL448212

CN(NC(=O)CS(=O)(=O)NN(C)C(=S)c1cccs1)C(=S)c1cccs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.43
HSP90AB1 P08238 1/20 0.43
GAA P10253 6/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 4/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PKM P14618 1/20 0.38
LMNA P02545 4/20 0.37
POLB P06746 2/20 0.37
HDAC1 Q13547 1/20 0.37
MAPK1 P28482 1/20 0.37
KCNH2 Q12809 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL464655 0.81 HSP90AA1 (0.68) HSP90AA1HSP90AB1GAAMEN1KMT2A
SCHEMBL448878 0.80 HSP90AA1 (0.45) HSP90AA1HSP90AB1KMT2ANPC1RAB9A
SCHEMBL445596 0.78 HSP90AA1 (0.59) HSP90AA1HSP90AB1GAAMEN1KMT2A
SCHEMBL15621595 0.77 HSP90AA1 (0.51) HSP90AA1HSP90AB1GAAMEN1KMT2A
SCHEMBL448959 0.77 HSP90AA1 (0.42) HSP90AA1HSP90AB1GAAMEN1KMT2A
SCHEMBL446362 0.75 HSP90AA1 (0.63) HSP90AA1HSP90AB1MEN1KMT2AALDH1A1
SCHEMBL445761 0.75 HSP90AA1 (0.59) HSP90AA1HSP90AB1GAAKMT2AALDH1A1
SCHEMBL445921 0.75 HSP90AA1 (0.49) HSP90AA1HSP90AB1GAAKMT2AALDH1A1
SCHEMBL2476616 0.75 HSP90AA1 (0.52) HSP90AA1HSP90AB1GAAMEN1KMT2A
SCHEMBL448654 0.73 HSP90AA1 (0.46) HSP90AA1HSP90AB1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680100-B2 Sulfonylhydrazide compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2014-03-25 US disclosed
US-8680100-B2 Sulfonylhydrazide compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2014-03-25 US disclosed
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-03-15 US disclosed
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-03-15 US disclosed
WO-2010065512-A2 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS PKD1, PKD2, PCNA HSP90AA1 2300/4885HSP90AB1 1711/4885GAA 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.